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Abstract
Background:  Recent observations indicate that human tumorous breast tissue metabolizes
progesterone differently than nontumorous breast tissue. Specifically, 5α-reduced metabolites (5α-
pregnanes, shown to stimulate cell proliferation and detachment) are produced at a significantly
higher rate in tumorous tissue, indicating increased 5α-reductase (5αR) activity. Conversely, the
activities of 3α-hydroxysteroid oxidoreductase (3α-HSO) and 20α-HSO enzymes appeared to be
higher in normal tissues. The elevated conversion to 5α-pregnanes occurred regardless of estrogen
(ER) or progesterone (PR) receptor levels. To gain insight into these differences, the activities and
expression of these progesterone converting enzymes were investigated in a nontumorigenic cell
line, MCF-10A (ER- and PR-negative), and the three tumorigenic cell lines, MDA-MB-231 (ER- and
PR-negative), MCF-7 and T-47D (ER- and PR-positive).
Methods:  For the enzyme activity studies, either whole cells were incubated with
[14C]progesterone for 2, 4, 8, and 24 hours, or the microsomal/cytosolic fraction was incubated
for 15–60 minutes with [3H]progesterone, and the metabolites were identified and quantified.
Semi-quantitative RT-PCR was employed to determine the relative levels of expression of 5αR
type1 (SRD5A1), 5αR type 2 (SRD5A2), 20α-HSO (AKR1C1), 3α-HSO type 2 (AKR1C3), 3α-HSO
type 3 (AKR1C2) and 3β-HSO (HSD3B1/HSD3B2) in the four cell lines using 18S rRNA as an internal
control.
Results:  The relative 5α-reductase activity, when considered as a ratio of 5α-pregnanes/4-
pregnenes, was 4.21 (± 0.49) for MCF-7 cells, 6.24 (± 1.14) for MDA-MB-231 cells, 4.62 (± 0.43)
for T-47D cells and 0.65 (± 0.07) for MCF-10A cells, constituting approximately 6.5-fold, 9.6-fold
and 7.1 fold higher conversion to 5α-pregnanes in the tumorigenic cells, respectively, than in the
nontumorigenic MCF-10A cells. Conversely, the 20α-HSO and 3α-HSO activities were significantly
higher (p < 0.001) in MCF-10A cells than in the other three cell types. In the MCF-10A cells, 20α-
HSO activity was 8-14-fold higher and the 3α-HSO activity was 2.5-5.4-fold higher than in the other
three cell types. The values of 5αR:20α-HSO ratios were 16.9 – 32.6-fold greater and the 5αR:3α-
HSO ratios were 5.2 – 10.5-fold greater in MCF-7, MDA-MB-231 and T-47D cells than in MCF-
10A cells. RT-PCR showed significantly higher expression of 5αR1 (p < 0.001), and lower
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expression of 20α-HSO (p < 0.001), 3α-HSO2 (p < 0.001), 3α-HSO3 (p < 0.001) in MCF-7, MDA-
MB-231 and T-47D cells than in MCF-10A cells.
Conclusion:  The findings provide the first evidence that the 5αR activity (leading to the
conversion of progesterone to the cancer promoting 5α-pregnanes) is significantly higher in the
tumorigenic MCF-7, MDA-MB-231 and T-47D breast cell lines than in the nontumorigenic MCF-
10A cell line. The higher 5αR activity coincides with significantly greater expression of 5αR1. On
the other hand, the activities of 20α-HSO and 3α-HSO are higher in the MCF-10A cells than in
MCF-7, MDA-MB-231 and T-47D cells; these differences in activity correlate with significantly
higher expression of 20α-HSO, 3α-HSO2 and 3α-HSO3 in MCF-10A cells. Changes in
progesterone metabolizing enzyme expression (resulting in enzyme activity changes) may be
responsible for stimulating breast cancer by increased production of tumor-promoting 5α-
pregnanes and decreased production of anti-cancer 20α – and 3α-4-pregnenes.
Background
Previous studies [1] have shown that breast tissue converts
progesterone to two classes of 21-carbon steroids: those
that retain the C4–5 double bond (4-pregnenes) and those
that are 5α-reduced (5α-pregnanes). The conversion to
5α-pregnanes, requiring the action of 5α-reductase (5αR),
is significantly higher in tumorous than in nontumorous
human breast tissue [1]. Exposure of human breast cell
lines (MCF-7, MCF-10A, and ZR-75-1) to 5α-pregnanes
results in changes associated with neoplasia, including in-
creased proliferation and decreased attachment [1], depo-
lymerization of F-actin [2] and decreases in adhesion
plaque-associated vinculin [2]. Exposure to 4-pregnenes
results, in general, in opposite (anti-cancer-like) effects
[1,2]. Breast tissue has also been shown to exhibit 3α-hy-
droxysteroid oxidoreductase (3α-HSO), 20α-HSO and
3β-HSO activities [1]. Activities of 3α-HSO and 20α-HSO
were higher in the normal tissue of matched tissue sam-
ples [1]. Additionally, specific but separate, high-affinity
receptors for the 5α-pregnane, 5α-pregnane-3,20-dione
and the 4-pregnene, 3α-hyroxy-4-pregnen-20-one, have
been identified in the plasma membrane fractions of
breast cancer cells [3].
The results from the previous studies [1–3] imply impor-
tant cancer regulating functions for autocrine/paracrine
progesterone metabolites and suggest regulatory roles for
5αR, 20α – and 3α(β)-HSO activities in human breast
cancer progression. In order to further study the role of
these enzymes in breast cancer it was of interest to deter-
mine if breast cell lines exhibit these activities and if gene
expression levels can be correlated to the levels of activity.
For comparisons we chose a breast epithelial cell line
(MCF-10A) known to be nontumorigenic [4] and three
human breast cancer cell lines (MCF-7, MDA-MB-231 and
T-47D) known to be tumorigenic [5,6] in athymic nude
mice. The MCF-10A cell line was derived from human fi-
brocystic mammary tissue and is estrogen (ER-) and pro-
gesterone (PR-) receptor negative [4]. The MCF-7, MDA-
MB-231 and T-47D cell lines were derived from human
breast adenocarcinoma, MCF-7 and T-47D cells being ER+
and PR+ [7] and estrogen-dependent for tumorigenicity
[5,6], and MDA-MB-231 cells being ER- and PR- [8] and
will form tumors with or without supplemental estrogen
[5]. Therefore, the objectives of the current studies were
(a) to compare the activities of 5αR, 20α-HSO, 3α-HSO
and 3β-HSO in one nontumorigenic and three tumori-
genic human breast cell lines, and (b) to determine if dif-
ferences in level of enzyme activities might be related to
differences in specific mRNA expression.
These studies show that 5αR activity is significantly higher
in MCF-7, MDA-MB-231 and T-47D cells than in MCF-
10A cells, resulting in significantly higher 5α-pregnane:4-
pregnene ratios in the tumorigenic (MCF-7, MDA-MB-
231 and T-47D) cell lines. Conversely, 20α-HSO and 3α-
HSO activities are significantly higher in the MCF-10A cell
line. The results also provide the first demonstration of
the expression of messenger RNA for 5αR type 1 (5αR1;
SRD5A1), 5αR type 2 (5αR2;  SRD5A2), 20α-HSO
(AKR1C1), 3α-HSO type 2 (3α-HSO2; AKR1C3), 3α-HSO
type 3 (3α-HSO3; AKR1C2) and 3β-HSO in breast cell
lines. Moreover, they show opposing expression patterns
for 5αR1 and 20α-(3α-)-HSOs in nontumorous (MCF-
10A) compared to the three tumorigenic cell lines.
Methods
Chemicals
[4-14C]Progesterone (55.4 mCi/mmol) and [1,2,6,7-
3H]progesterone (114.8 Ci/mmol) were purchased from
Perkin Elmer Life Sciences (New England Nuclear)
(Woodbridge, Ontario). [1,2,6,7-3H]3α-Hydroxy-4-preg-
nen-20-one (3αHP) was synthesized from [1,2,6,7-
3H]progesterone by published procedures [9]. Unlabeled
3αHP, 3βHP, and 4-pregnene-3α (β),20α(β)-diols were
prepared as described previously [10,11]. Other unla-
beled steroids were purchased from Steraloids Inc
(Wilton, N.H.) or Sigma Chemical Co. (Oakville, ON).
Cell culture media, insulin, penicillin, streptomycin, hy-
drocortisone, cholera toxin, and epidermal growth factorBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/9
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were from Sigma and serum was purchased from Invitro-
gen (Burlington, ON). N-methyl-bis-trifluoroacetamide
and  N,O-bis(trimethylsilyl)trifluoroacetamide were ob-
tained from Pierce Chemical Co. (Rockford, IL). Other
chemicals and solvents were of appropriate analytical
grade and were purchased from BDH Inc., (Toronto, ON),
VWR (Mississauga, ON) or Fisher Scientific Ltd. (Toronto,
ON). Thin layer chromatography (TLC) plates (EM Sci-
ence, silica gel 60 F254, 250 µm thickness (20 × 20 cm; 2.5
× 7.5 cm) were obtained from VWR. Medical X-ray film
(X-OMAT R) was from Kodak.
Cell Culture
MCF-7 cells came from Dr. R. Shiu through the courtesy
of Dr. J. Wimalasena and the MDA-MB-231, T-47D and
MCF-10A cells were purchased from the American Type
Culture Collection (Manassas, VA). The MCF-7, MDA-
MB-231 and MCF-10A cells were grown in a 1:1 Ham's
F12 Medium and Dulbecco's Modified Eagle's Medium
with 2 mM L-glutamine. The T-47D cells were grown in
RPMI-1640 with L-glutamine. The medium was supple-
mented with 5% calf serum (MCF-7), 10% calf serum
(MDA-MB-231), 10% Fetal Bovine Serum (T-47D) or 5%
horse serum (MCF-10A), 100 units/ml penicillin, 78
units/ml streptomycin, 10 µg/ml insulin and 1.2 mg/ml
sodium bicarbonate. During the subculture period, MCF-
10A cells were further supplemented with 0.5 mg/L hy-
drocortisone, 0.1 µg /ml cholera toxin and 0.02 µg /ml ep-
idermal growth factor as recommended [4]. Cells were
grown in T75 flasks until 80% confluence before harvest-
ing (for cell-free cytosolic/microsomal enzyme activity
studies) or subculturing in 35 mm dishes (for expression
or whole cell enzyme activity studies). For the expression
studies, cells were seeded at 300,000 cells per 35 mm dish
in their own media, allowed to attach for 24 hours, and
then grown in serum free MCF-7 media for 48 hours prior
to harvest. For the in vivo enzyme activity studies, cells
were seeded at 106 cells, allowed to attach for 24 hours,
medium was replaced with medium containing [14C]pro-
gesterone and incubation was continued for 2, 4, 8, or 24
hours before termination and extraction as reported
[1,12,13]. Cells were maintained in a humidified incuba-
tor at 37°C and a 5% CO2 atmosphere.
Enzyme Activities – Whole Cells in Culture
For the in vivo enzyme activity studies cells were seeded in
35 mm plastic (Falcon) dishes at approximately 750 K
cells per dish and allowed to attach overnight. Some dish-
es were used to determine cell numbers by hemocytome-
ter at 0 and 24 hours after the start of incubations.
Medium was removed and replaced with fresh medium
containing [14C]progesterone (0.2 µCi). Cell numbers
were determined by hemocytometer in parallel dishes in-
cubated without [14C]progesterone for 0 or 24 hours. Ad-
ditional controls consisted of incubations of medium
containing [14C]progesterone in the absence of cells. Each
treatment consisted of 3–4 dishes and the progesterone
metabolism of each cell type was examined in at least two
separate experiments. Incubations were terminated at 0
(control), 2, 4, 8 and 24 hours by removing cells and me-
dia to siliconized glass extraction tubes on ice and adding
2.0 ml ice cold 0.05 M NaOH and 6.0 ml ether:chloro-
form (4:1). Known amounts of unlabeled steroid stand-
ards were added for recovery calculations and
identification purposes.
The [14C]progesterone metabolites were extracted three
times with the ether:chloroform mixture, the extracts were
delipidated, run two-dimensionally on TLC, identified by
TLC-autoradiograpy, high performance liquid chromatog-
raphy (HPLC), derivatization, capillary gas chromatogra-
phy-mass spectrometry and quantified by scintillation
spectrometry as previously described [1,12,13]. The
amount of each metabolite produced was determined as
percent of the total, and, following corrections for proce-
dural losses, was calculated as ng per hour per 106 cells.
Because these values had begun to decrease somewhat for
the main metabolites at 24 hours, the values given in this
report are those determined from the 4- and 8-hour
incubations.
Enzyme Activities in Microsomal/Cytosolic Fractions
Each cell type, grown in 8–10 T75 flasks until 80–90%
confluent, was harvested, washed in balanced salt solu-
tion, and brought up in 3 mL of ice-cold phosphate buff-
ered sucrose/glycerol solution (Na2HPO4, 0.8 mM;
NaH2PO4, 0.2 mM; sucrose 250 mM, EDTA, 1.0 mM;
glycerol, 20% v/v; pH 7.2). Cells were homogenized in a
tight-fitting glass-glass homogenizer (40 strokes), centri-
fuged (0°C) at 12,000 × g for 10 minutes, and the super-
natants (designated as the microsomal/cytosolic
fractions) were stored at -80°C until used. Protein concen-
trations were determined by the method of Bradford [14].
Enzyme Assays. Reductive enzyme assays were conducted
by incubating cytosolic/microsomal fractions (100 µL) in
phosphate buffer (Na/Na, 0.05 M, pH 7.0) containing
NADH and NADPH (0.4 mM final concentration) and
[1,2,6,7 3H]progesterone (350,000 dpm per 455 pg) for
15, 30, or 60 minutes in a shaking water bath at 37°C. The
reaction was stopped by immersing the tubes in ice, add-
ing 0.5 mL ice-cold 0.05 M NaOH and 3.0 mL ether/
CH2Cl2 (9:1). Following two extractions (3 mL each) with
ether/CH2Cl2, the steroid metabolites were separated by
TLC (25 × 75 mm; chloroform/acetone, 9:1) and HPLC
(C18, methanol/water, 72:28) and quantified by scintilla-
tion spectrometry.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/9
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RNA Isolation and Reverse Transcription
Total RNA was extracted from the cells using TRIzol® rea-
gent (Invitrogen) following the manufacturer's protocol.
RNA yields were measured by spectrophotometry and
RNA integrity was analysed by agarose gel electrophoresis.
Prior to reverse transcription, RNA was treated with
DNase I for 30 minutes at 37°C using a DNA-free™ kit
(Ambion). Complementary DNA (cDNA) was obtained
from 2.0 µg of DNase treated total RNA using 200 U
Moloney Murine Leukemia Virus (MMLV) reverse tran-
scriptase (Invitrogen) and random hexamer primers (Inv-
itrogen) in a total volume of 20 µl following the
manufacturers protocol. To exclude amplification of ge-
nomic DNA, experiments included conditions in which
the reverse transcriptase enzyme was omitted.
Semi-Quantitative RT-PCR
Prior to semi-quantitative RT-PCR, primers for the follow-
ing commonly used housekeeping genes were tested for
variability of expression between cell lines: 18S rRNA, β-
actin, glyceraldehyde-3-phosphate dehydrogenase
(G3PDH) and cyclophilin. Based on least variation of ex-
pression between cell lines, 18S was chosen as the control
for the enzyme expression studies. The PCR primers were
purchased from Invitrogen with sequences given in table
1[15–17,43]. PCR conditions for the primer sets were as
follows: 95°C denature for 4 minutes followed by cycling,
each cycle with a 20 second denature at 94°C, a 30 second
anneal at 62°C, and a 30 second extension at 72°C. Cy-
cling was followed by a final extension for 4 minutes at
72°C. For each reaction an 2 µl aliquot of cDNA product
was amplified in a 25 µl total volume using 1.25 U of Plat-
inum Taq DNA Polymerase (Invitrogen), 2 mM MgCl, 0.2
mM dNTP's, 2 mM each primer. The same cycling condi-
tions and PCR reagent concentrations were used for each
set of primers. The kinetics of the PCR reactions for each
primer set was determined by varying the amount of tem-
plate and the number of cycles. All PCR product identities
were confirmed by separation on a 1.5% agarose gel and
sequencing at the Robarts Research Institute Sequencing
Facility (London, ON).
For each cDNA sample, aliquots were amplified for 13 cy-
cles with the 18S rRNA primers, 25 cycles with the 5αR1
primers, 33 cycles with the 5αR2 primers and 22 and 25
cycles with the 20α-HSD, 3α-HSD2 and 3α-HSD3 prim-
ers respectively. Products were separated on 9% polyacry-
lamide gels and the intensities of the appropriate bands
were quantified by Quantity One 4.2.1 Gel Doc Software
(BioRad Laboratories) and expressed as total pixel value,
based on intensity and number of pixels per band. Results
are expressed as ratios of the total pixel value of the band
of interest to the total pixel value of the 18S rRNA band.
Each ratio represents the average of duplicate PCRs per-
formed for each gene from 5–7 replicate experiments.
Statistics
Results are expressed as mean ± SEM and were analysed by
one-way ANOVA followed by Tukey's pairwise compari-
sons to detect significant differences between groups, p <
0.05, using the computer program InStat (GraphPad, San
Diego, CA).
Results
Enzyme Activities in Cultured Cells
Figure 1 shows sample autoradiographs of TLC-separated
[14C]progesterone and its metabolites formed by two of
the four (MCF-7 and MCF-10A) cell lines during an 8 h in-
cubation. The main metabolites of [14C]progesterone
were identified as: 5α-pregnane-3,20-dione, 5α-pregnan-
3α-ol-20-one, 5α-pregnan-20α-ol-3-one, 5α-pregnan-3β-
ol-20-one, 5α-pregnane-3α (β), 20α-diols, 4-pregnen-3α-
ol-20-one (3αHP), 4-pregnen-20α-ol-3-one (20αDHP),
and 4-pregnene-3α, 20α-diol (The structures of the me-
tabolites are shown in Figure 6). The 5α-reductase activity
was calculated from the total amounts of all 5α-reduced
metabolites. The 3α-HSO, 3β-HSO, and 20α-HSO activi-
ties were calculated from the total amounts of all 3α-hy-
Table 1: Primer sequences (upstream; downstream) used in the RT-PCR analyses.
cDNA Sequence Size Reference
SRD5A1 (5αR1) 5'-TGG CGC TTC TCT ATG GAC TT-3' 5'-GGA AGC AAC ACT GCA GTT GA-3' 368 bp [15]
SRD5A2 (5αR2) 5'-CAT ACG GTT TAG CTT GGG TGT-3' 5'-GCT TTC CGA GAT TTG GGG TAG-3' 315 bp [16]
AKR1C1 (20α(3α)HSD) 5'-GTA AAG CTT TAG AGG CCA C-3' 5'-CAC CCA TGC TTC TTC TCG G-3' 590 bp [43]
AKR1C2 (3αHSD3) 5'-GTA AAG CTC TAG AGG CCG T-3' 5'-CAC CCA TGG TTC TTC TCG A-3' 590 bp [43]
AKR1C3 (3α(17β)HSD2) 5'-GTA AAG CTT TGG AGG TCA C-3' 5'-CAC CCA TCG TTT GTC TCG T-3' 590 bp [43]
AKR1C4 (3αHSD1) 5'-ACA GAG CTG TAG AGG TCA C-3' 5-CAC CCA TAG TTT ATG TCG T-3' 590 bp [43]
HSD3B1 &HSD3B2 (3βHSD) 5'-GCT GGA GCT GCC TTG TGA C-3' 5'-CCC GGC TAC CTC TAT GCT ACT-3' 383 bp (M.J. 
Lewis)
18S rRNA 5'-GTA ACC CGT TGA ACC CCA TT-3' 5'-CCA TCC AAT CGG TAG TAG CG-3' 131 bp [17]BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/9
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droxy, 3β-hydroxy, and 20α-hydroxy metabolites,
respectively.
5α-Reductase
Figure 2a shows that 5α-pregnanes comprised 80–89% of
all progesterone metabolites in MCF-7, MDA-MB-231 and
T-47D cells, and about 39% in the MCF-10A cells. When
considering the metabolites as a ratio of 5α-pregnanes/4-
pregnenes (Fig. 2b) the relative values for MCF-7, MDA-
MB-231 and T-47D cells are significantly (p < 0.05-p <
0.001; 6.5-, 9.6-, and 7.1-fold) greater than for MCF-10A
cells. Figure 2c shows that 5αR activity, calculated as 5α-
pregnanes formed (pmoles/h/106 cells), is significantly (p
< 0.05-0.01) higher in MCF-7, MDA-MB-231 and T-47D
cells than in MCF-10A cells.
20α-HSO, 3α-HSO and 3β-HSO
The 20α-HSO activity was not significantly different (p >
0.05) between MCF-7, MDA-MB-231 and T-47D cells but
was significantly (p < 0.001; 8.09–13.98-fold) higher in
MCF-10A than in the other three cell types (Fig. 3a). 3α-
HSO activity was not significantly (p > 0.05) different be-
tween MCF-7, MDA-MB-231 and T-47D cells but was sig-
nificantly (p < 0.001; 2.5–5.4-fold) higher in MCF-10A
Figure 1
Sample autoradiographs of TLCs showing 14C-labeled metabolites of progesterone in MCF-7 and MCF-10A cells following an 
8-hour incubation with [14C]progesterone (P). The main metabolites identified and quantified for these enzyme activity studies 
are: (1) 5α-pregnane-3,20-dione, (2) 5α-pregnan-3α-ol-20-one, (3) 5α-pregnan-20α-ol-3-one, (4) 5α-pregnan-3β-ol-20-one, 
(5) 4-pregnen-3α-ol-20-one (3αHP), (6) 4-pregnen-20α-ol-3-one (20αDHP), (7) 5α-pregnane-3α (β), 20α-diol, (8) 4-preg-
nene-3α,20α-diol. The extracts were spotted at the origin and the plates were run 2 × in solvent system 1 and 3 × in solvent 
system 2 in the directions indicated, as described under Methods, and the films were exposed for 8 days. Note greater size/
intensity of 5α-pregnane spots (Nos. 1–4, 7) in MCF-7 cells, and greater size/intensity of 4-pregnene spots (No. 5 and 6) in 
MCF-10A cells.
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than in the other three cell types (Fig. 3b). 3β-HSO activi-
ties (ranging between 9.3 and 29.2 pmoles/h/106 cells)
were not significantly different (p > 0.05) between cell
types (Fig. 3c).
Activity Ratios
When calculated as ratio of 5αR:20α-HSO (Fig. 4a), val-
ues for MCF-7, MDA-MB-231 and T-47D cells were not
significantly different (p > 0.05) from each other but were
significantly (p < 0.01; 16.9-, 26.9- and 32.6-fold, respec-
tively) greater than for MCF-10A cells. The 5αR:3α-HSO
ratios for MDA-MB-231 and T-47D cells were significantly
(p < 0.05) greater than for MCF-7 cells and the ratio for
MCF-10A cells was significantly (p < 0.001) lower than for
the other three cell lines (Fig. 4b).
Enzyme Activities in Microsomal/Cytosolic Fractions
Incubating whole cells in their normal medium in the
presence of [14C]progesterone results in both reductive
and oxidative reactions promoted by the endogenous co-
factors. In a cell-free system it is possible to determine
more precisely the reductive or oxidative reaction veloci-
ties by supplying the corresponding cofactors and control-
ling the pH. More direct measurements of reductive
enzyme activities were obtained by incubating microsom-
al/cytosolic fractions of cells with [3H]progesterone (at
pH 7.0) in the presence of NADH and NADPH. The re-
sults, presented in Table 2 as the mean 5αR, 20α-HSO and
3α-HSO activities (pg/hour/mg protein or as percent of
total enzyme activities) for duplicate incubations, in gen-
eral are in line with the findings in cultured cells. The ac-
Figure 2
Relative 5α-reductase (5αR) activities in MCF-7, MDA-MB-231, T-47D, and MCF-10A cells, calculated (mean ± SEM; n = 3–6) 
as (a) percent of total metabolites, (b) ratio of 5α-pregnanes:4-pregnenes, and (c) pmoles per hour per 106 cells of 5α-reduced 
metabolites produced. In (a) the mean levels of 4-pregnenes are significantly different from the mean levels of 5α-pregnanes at 
p < 0.001. In (b) and (c), *, **, and *** indicate significant differences from MCF-10A cells at p < 0.05, p < 0.01, and p < 0.001, 
respectively.
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tivity of 5αR is lowest and the activities of 20α-HSO and
3α-HSO are highest in MCF-10A cells resulting in marked-
ly lower ratios of 5αR:20α-HSO and 5αR:3α-HSO than in
MCF-7, MDA-MB-231 and T-47D cells (Table 2). The oxi-
dative 3α-HSO activity (determined in MCF-7, T-47D and
MCF-10A microsomal/cytosolic fractions using the sub-
strate, [3H]3αHP, and cofactors, NAD and NADP, at pH
8.0) was about 8- and 18-fold higher in MCF-10A than in
MCF-7 and T-47D cells, respectively (results not shown).
Semi-quantitative RT-PCR
RT-PCR followed by direct product sequencing confirmed
that 5αR1, 5αR2, 20α-HSO, 3α-HSO2, 3α-HSO3 and 3β-
HSO type 1 are expressed in MCF-7, MDA-MB-231, T-47D
and MCF-10A cells. PCR of RT reactions lacking reverse
transcriptase enzyme resulted in no amplification.
To determine the range of accuracy of quantification for a
specific cycle number, PCR was performed using varying
amounts (1 µl, 2 µl, 4 µl, 8 µl) of MCF-7 cDNA as tem-
plate. The total pixel value of respective 5αR1 (25 cycles)
and 18S (13 cycles) bands, determined for 3–5 replicate
amplifications, increased linearly between 1 µl and 8 µl of
RT template. Linear regression analysis indicated a good-
ness of fit index of 0.859 and 0.967 for 5αR1 and 18S, re-
spectively, and correlation (data vs. model) of 0.999 for
each. When amplifying templates of 16.0 µl equivalent or
greater the slopes decreased indicating that the software
underestimated the pixel values when too much template
Figure 3
Activities (mean ± SEM; n = 3–6) of (a) 20α-HSO, (b) 3α-HSO and (c) 3β-HSO in MCF-7, MDA-MB-231, T-47D, and MCF-10A 
cells, calculated from the metabolites as pmoles/hour/106 cells. ***, significantly different from MCF-7, MDA-MB-231, and T-
47D cells at p < 0.001.
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is amplified. When less than 1.0 µl equivalent amounts of
template were amplified, the bands were invisible or
barely visible and the software tended to underestimate
the pixel values. The results showed that quantification by
this procedure is linear over an 8-fold range for any single
cycle number. Based on these findings we determined that
18S could be quantified in the 4 cell types by amplifying
for 13 cycles, 5αR1 could be quantified by amplifying for
25 cycles, and 5αR2 could be quantified by amplifying for
33 cycles. Due to a greater variability of expression be-
tween cell types, 20α-HSD, 3α-HSD2 and 3α-HSD3 were
amplified for 22 and 25 cycles to cover a greater range of
expression.
Expression of 5αR1 and 5αR2
Expression of 5αR1 mRNA, shown in Figure 5a, was great-
er in MCF-7, MDA-MB-231, and T-47D cells than in MCF-
10A cells. Semi-quantitative RT-PCR analysis of 5αR1 (rel-
ative to 18S mRNA) gave values of 2.55 (± 0.10) for MCF-
7 cells, 2.13 (± 0.17) for MDA-MB-231 cells, 2.76 (± 0.22)
Figure 4
Ratios of (a) 5αR:20α-HSO and (b) 5αR:3α-HSO activities in MCF-7, MDA-MB-231, T-47D, and MCF-10A cells. *, **, and *** 
indicate significant differences from MCF-10A cells at p < 0.05, p < 0.01, and p < 0.001, respectively.
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for T-47D cells and 1.09 (± 0.12) for MCF-10A cells (Fig.
5a, right panel). This represents significant (p < 0.001)
2.34-, 1.95-, and 2.53-fold higher expression, respectively,
for MCF-7, MDA-MB-231 and T-47D cells than for MCF-
10A cells. RT-PCR analysis for 5αR2 showed statistically
insignificant differences between cell types (Fig. 5b). The
mean (± SEM) of 5αR2/18S ratios (n = 5–6) were 0.74 (±
0.05), 0.59 (± 0.07), 0.81 (± 0.10), and 0.87 (± 0.11) for
MCF-7, MDA-MB-231, T-47D and MCF-10A cells,
respectively.
Expression of 20α-HSO, 3α-HSD2, 3α-HSD3 and 3β-HSD
A representative gel showing 20α-HSO (AKR1C1) expres-
sion in the four cell types is shown in Figure 5c. The ratio
of 20α-HSO to 18S rRNA (n = 6) was 1.40 (± 0.10), 3.00
(± 0.24), 0.96 (± 0.10) and 8.59 (± 0.91) in the MCF-7,
MDA-MB-231, T-47D and MCF-10A cells respectively.
This represents a significant (p < 0.001) 6.1-, 2.9- and 8.9-
fold greater expression of 20αHSO in MCF-10A cells than
in MCF-7, MDA-MB-231, and T-47D cells, respectively.
We were unable to detect mRNA expression of 3α-HSO
type 1 (AKR1C4) in any of the four cell types. A represent-
ative gel showing 3α-HSO2 (AKR1C3) expression in the
four cell types is shown in Figure 5d. The ratio of 3α-
HSO2 to 18s rRNA (n = 6) was 0.38 (± 0.30), 4.12 (±
0.26), 0.82 (± 0.09) and 6.87 (± 0.74) in the MCF-7,
MDA-MB-231, T-47D and MCF-10A cells, respectively.
This represents significant (p < 0.001) 18.1-, 1.6- and 8.4-
fold greater expression of 3α-HSO2 in MCF-10A cells than
in MCF-7, MDA-MB-231, and T-47D cells, respectively.
The expression of 3α-HSO2 in MDA-MB-231 cells was
also significantly (p < 0.001) higher than in MCF-7 and T-
47D cells.
A representative gel showing 3α-HSO3 (AKR1C2) expres-
sion in the four cell types is shown in Figure 5e. The ratio
of 3α-HSO3 was 1.59 (± 0.19), 0.26 (± 0.03), 1.54 (±
0.17) and 17.18 (0.95) in the MCF-7, MDA-MB-231, T-
47D and MCF-10A cells, respectively. This represents
10.8-, >20- and 11.2-fold greater expression (p < 0.001) of
3α-HSO3 in MCF-10A cells than in MCF-7, MDA-MB-231
and T-47D cells, respectively.
3β-HSD Type 1 (HSD3B1) was expressed in all cells but
the levels were inconsistent for reliable quantification (re-
sults not shown). 3β-HSO type 2 expression was not de-
tected in any of the four cell types.
Discussion
Previous  in vitro metabolism studies have shown that
mammary tissue from mouse [18], rat [19–21] and hu-
man [1,22,23] can convert progesterone to metabolites
whose formation would require the action of the
enzymes, 5αR, 3α-HSO, 3β-HSO and 20α-HSO. The re-
sults of the current investigation show that MCF-7, MDA-
MB-231, T-47D and MCF-10A human breast cell lines re-
tain the activities of these progesterone metabolizing en-
zymes. An outline of the major metabolic pathways and
the positions of the enzymes in the breast cell lines is pre-
sented in Figure 6. Of interest is that these pathways ap-
pear to be the same as those found in breast tissues [1].
Moreover, differences between tumorous and nontumor-
ous breast tissue in terms of relative activities of enzymes
such as 5αR and 20α-HSO [1,18,19,23] were observed be-
tween tumorigenic and nontumorigenic cell lines in the
present study.
5α-Reductase
The enzyme responsible for the conversion of 4-ene ster-
oids to 5α-reduced steroids is 4-ene-steroid 5α-reductase,
known commonly as 5α-reductase (5αR; EC 1.3.99.5)
[24]. There are two known isoforms of the human 5α-re-
ductase, namely type 1 (5αR1) and type 2 (5αR2) [24–
26]. 5αR1, which is encoded by the SRD5A1 gene and is
composed of 259 amino acids, has an optimum pH of 6–
9, whereas 5αR2, encoded by the SRD5A2 gene, and com-
posed of 254 amino acids, has an optimum pH of 5.5
[27]. 5αR1 has been detected in various androgen-inde-
pendent organs, such as the liver and brain [28]. 5αR2 has
been found predominantly in androgen-dependent or-
gans, such as epididymis and prostate [24,28] and its role
Table 2: 5α-Reductase, 20α-HSO and 3α-HSO activities in microsomes/cytosol of breast cell lines.
Cells 5αR2 0 α-HSO 
(reductive)
3α-HSO 
(reductive)
5αR/20α-HSO 5αR/3α-HSO
MCF-7 228.6 (86.5) 17.9 (6.8) 17.9 (6.8) 12.77 12.77
MDA231 186.2 (75.3) 49.8 (20.1) 11.3 (4.6) 3.74 16.48
T-47D 82.1 (74.5) 21.8 (19.8) 6.3 (5.7) 3.77 13.03
MCF-10A 78.3 (7.6) 845.1 (81.4) 114.2 (11.0) 0.93 0.69
The 10,000 × g supernatant of cell homogenates was incubated with NADH, NADPH and [3H]progesterone, and enzyme activities were deter-
mined by quantifying metabolites formed as a result of specific enzyme actions (See Methods for details). Values (mean from two experiments) are 
given as pg/hour/mg protein; the values in brackets show the percent of total enzyme activities for a particular cell type.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/9
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Figure 5
Representative gels showing the relative expression of (a) 5αR1, (b) 5αR2, (c) 20α-HSO, (d) 3α-HSO type 2, and (e) 3α-HSO 
type 3 in MCF-7 (lane 2), MDA-MB-231 (lane 3), T-47D (lane 4), and MCF-10A (lane 5) cells. In each case aliquots of cDNA 
were amplified with gene-specific primers, run on 9% polyacrylamide gels and the bands were quantified as described under 
Methods. Each right panels shows computer-assisted quantification of data calculated as ratios against 18S rRNA (mean ± SEM) 
from 6 separate experiments. *** significantly different from MCF-7, MDA-MB-231, and T-47D cells at p < 0.001.
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Figure 6
Progesterone metabolizing enzymes and pathways in MCF-7, MDA-MB-231, T-47D, and MCF-10A cells. Progesterone is con-
verted to 5α-pregnane-3,20-dione (5α-P-3,20-dione) by 5αR, to 4-pregnen-3α-ol-20-one (3αHP) by 3α-HSO, or to 4-preg-
nen-20α-ol-3-one (20αDHP) by 20α-HSO. Each of the 4-pregnenes can be 5α-reduced by 5αR, in a one-way reaction, to the 
respective 5α-pregnane. The activities of 3α-HSO and 20α-HSO are reversible and control reductive and oxidative inter-con-
versions within the 4-pregnenes (inner ring of metabolites) or 5α-pregnanes (outer ring of metabolites). Identification of 5α-
pregnan-3β-ol-20-one as a metabolite of all four cell types, indicates the presence of 3β-HSO activity, but at this time a full 
pathway of 3β-reduction/oxidation is not identified.
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in prostate cancer has been extensively studied. Recently
5αR1 and 5αR2 were located in human breast carcinoma
and were studied in relation to 5α-reduction of testoster-
one [29]. Although several studies have recently examined
SRD5A2 polymorphisms in association with breast cancer
[30–32], to date no study has addressed the relative ex-
pression of 5αR1 and 5αR2 in tumorous and normal
breast tissues or breast cell lines.
Tumorous mammary gland tissue has a greater ability to
convert progesterone to 5α-reduced metabolites (5α-preg-
nanes) than nontumorous tissue [1,18,19,23]. The results
of the present study provide the first demonstration that
MCF-7, MDA-MB-231 and T-47D human breast cell lines
have significantly greater ability to convert progesterone
to 5α-pregnanes than the MCF-10A human breast cell
line. Conversion of progesterone to 5α-pregnanes is the
result of 5α-reductase activity. The quantitative differenc-
es in 5α-reductase activities between cell lines do not ap-
pear to be related to the presence or absence of ER or PR,
since significantly higher (1.9–3.3-fold) 5α-reductase ac-
tivity was evident in MCF-7 and T-47D (ER-positive and
PR-positive) as well as MDA-MB-231 (ER-negative and
PR-negative) cells than in the ER/PR-negative MCF-10A
cells. The one consistent difference is that MCF-7, MDA-
MB231 and T-47D cells will form tumors [5,6], whereas
MCF-10A will not form tumors [4] in immunodeficient
mice. These results from cell lines are consistent with re-
sults from matched breast tissues of patients in which tu-
morous tissue exhibited significantly higher progesterone
5α-reductase activity than nontumorous tissue, regardless
of presence or absence of ER and/or PR [1]. The 5α-preg-
nanes:4-pregnenes ratio was about 8-fold higher in tu-
morous than in nontumorous breast tissue after an 8-hour
incubation with [14C]progesterone [1]. Studies with
breast cell lines, showing that 5α-pregnanes stimulate
proliferation and decrease attachment of cells [1,2]
prompted us to suggest that neoplasia in human breast
may be promoted by increases in ratio of 5α-pregnanes:4-
pregnenes. In the current studies, the ratio of 5α-preg-
nanes:4-pregnenes in the tumorigenic cells was 6.5-fold
higher for MCF-7 cells, 9.6-fold higher for MDA-MB-231
cells, and 7.1-fold higher for T-47D cells than for the non-
tumorigenic MCF-10A cells. Therefore, both tissue and
breast cell line studies suggest that an elevated level of
progesterone 5α-reductase activity may be an indicator of
breast tumorigenesis, regardless of presence or absence of
ER and/or PR. However, it should be noted that only a sin-
gle nontumorous cell line was examined and it will be
necessary to study other "normal" breast cell lines before
making generalizations regarding the relationship be-
tween changes in steroid enzyme activity and tumori-
genicity in human breast cell lines.
Several factors can account for increases in 5α-reductase
activity. In vivo, increases in enzyme activity can result
from increased synthesis of enzyme due to increased ex-
pression of the mRNA coding for the enzyme, or from
changes in the milieu in which the enzymes operate (such
as temperature and pH, and concentrations of cofactors,
substrates, products, competitors, ions, phospholipids
and other molecules). In in vitro experiments, the milieu
is carefully controlled to be constant for all the incuba-
tions and therefore observed differences can be more eas-
ily ascribed to differences in enzyme amounts resulting
from increased expression. The results of the RT-PCR stud-
ies show that the expression of 5αR1 is significantly
greater in MCF-7, MDA-MB-231 and T-47D cells than in
MCF-10A cells. Although 5αR2 is expressed approximate-
ly equally in the four cell types, the abundance of 5αR1
mRNA transcripts greatly exceeds that of the 5αR2
transcripts. Using identical PCR conditions it required 8–
10 more PCR cycles to amplify a 5αR2 band to the inten-
sity of a 5αR1 band in each of the cell types. Since each cy-
cle theoretically results in a doubling of PCR product,
5αR1 mRNA appears to be present at levels in the range of
about 250–1000 fold higher than the 5αR2 mRNA. Al-
though this can only be considered a qualitative observa-
tion, it appears reasonable to conclude that 5αR1 mRNA
represents the predominant 5αR mRNA present in each of
the four cell types tested here. Further, the differences in
expression of 5αR1 (Fig. 5a) between cell types (high in
MCF-7, MDA-MB-231 and T-47D cells and low in MCF-
10A cells) in general parallel the differences in total 5α-re-
ductase activities (Fig. 2). It was also recently demonstrat-
ed by immunohistochemistry and RT-PCR that 5αR1 is
the main isoform expressed in human breast carcinomas
[29] and that 5αR2 may not be associated with risk of
breast cancer [30–32]. These observations provide strong
evidence that 5αR1 is the primary 5α-reductase expressed
in these cell lines and that the differences in 5α-pregnane
production between the cells is due primarily to a differ-
ence in 5αR1 expression. This does not suggest, however,
that 5αR2 may not play any role in progesterone metabo-
lism in these cells under certain limiting conditions. Dif-
ferences in biochemical [33] and pharmacological
properties [34] and tissue pattern of expression [28,33],
and affinities for substrates [33,35], have suggested dis-
tinct physiological functions for 5αR1 and 5αR2. As in the
case of 5α-reductase activity, the presence or absence of
ER and PR do not appear to be related to 5α-reductase
expression.
The role of 5α-reduction of androgens in prostatic hyper-
plasia [36] and carcinoma [37] as it relates to 5α-dihy-
drotestosterone production [38] and 5α-reductase gene
expression [39] are well recognized. The potential impor-
tance of 5α-reduction of progesterone in breast cancer has
only recently received attention [1]. The studies presentedBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/9
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here on breast cell lines further suggest a link between tu-
morigenicity and increased 5α-reductase activity. If the
5α-pregnanes resulting from progesterone 5α-reductase
activity are involved in the risk and development of breast
cancer and if local 5α-reduction of progesterone can
influence or be influenced by the behavior of tumors,
then changes in expression of 5α-reductase may have im-
portant implications for the prevention, therapy and bio-
logical understanding of breast cancer. Moreover,
tumorigenic and nontumorigenic breast cell lines may
provide a useful in vitro system for studying the control of
5α-reductase activity and expression in breast cancer.
The 20α – and 3α-(3β)-Hydroxysteroid Oxidoreductases
The formation of progesterone metabolites by breast tis-
sue also involves the activities of 3α-HSO, 20α-HSO and
3β-HSO, as evidenced by the formation of the metabo-
lites: 20α-hydoxy-4-pregnen-3-one (20αDHP), 20α-hy-
droxy-5α-pregnan-3-one, 3α-hydroxy-4-pregnen-20-one
(3αHP), 3α-hydroxy-5α-pregnan-20-one, 3β-hydroxy-
5α-pregnan-20-one, 4-pregnene-3α,20α-diol, and 5α-
pregnane-3α (β),20α-diol.
20α-HSO is responsible for the reductive/oxidative inter-
conversions of progesterone and 20αDHP, 3αHP and 4-
pregnene-3α,20α-diol, 5α-pregnane-3,20-dione and 20α-
hydroxy-5α-pregnan-3-one, and 5α-pregnan-3α ( β)-ol-
20-one and 5α-pregnane-3α ( β),20α-diol. Our report
shows that the 20α-HSO activity was significantly higher
in MCF-10A cells than in the three other cell lines and that
this activity resulted primarily in 4-pregnene-20α-hydroxy
steroids (20αDHP and 4-pregnene-3α,20α-diol). Higher
levels of 20α-HSO activity have been reported in normal
human [1] and rat [19] mammary gland tissue than in re-
spective tumorous tissues. Human 20α-HSO is mainly as-
sociated with microsomes [40]. Its characterization from
human skin [41] showed that human 20α-HSO preferen-
tially catalyzes the reduction of progesterone to 20αDHP
with relatively low reverse (oxidative) activity.
Human 20α-HSO is a member of the aldo-keto reductase
(AKR) gene superfamily [42,43]. Expression of 20α-HSO
mRNA has been demonstrated in a number of tissues, in-
cluding mammary gland [41]. AKRs are monomeric 37
kDa proteins and are NAD(P)(H)-dependent [44]. The
isoform AKR1C1 is predominantly a 20α-HSO [42] al-
though the isoforms AKR1C2-AKR1C4 are also able to re-
duce progesterone to 20αDHP and oxidize 20αDHP to
progesterone [43]. The relative abundance of these isofor-
ms in MCF-7, MDA-MB-231, T-47D and MCF-10A cells
was investigated in our studies by RT-PCR and showed
significantly higher expression of AKR1C1, AKR1C2 and
AKR1C3 mRNA in MCF-10A than in the other cells. These
higher levels of expression suggest that the higher 20α-
HSO activity observed in the MCF-10A cell progesterone
metabolism studies is due to higher levels of AKR1C1
(and perhaps the other AKR isozyme) mRNA(s).
Human 3α-HSO is responsible for the interconversions of
3-oxo and 3α-hydroxy steroids and in the case of proges-
terone metabolism, results in interconversions between
progesterone and 3αHP, 20αDHP and 4-pregnene-
3α,20α-diol, 5α-pregnane-3,20-dione and 3α-hydroxy-
5α-pregnan-20-one, 20α-hydroxy-5α-pregnan-3-one and
5α-pregnan-3α,20α-diol. The 3α-HSO activities for MCF-
7, MDA-MB-231 and T-47D cells (5–10 pmoles/106 cells/
hour) were about 2.5–5.5-fold lower than the 3α-HSO ac-
tivity of MCF-10A cells. Interestingly, in matched breast
tissue samples [1] the 3α-reductive activity was 2.9- to 3.3-
fold higher in normal (nontumorous) than in tumorous
breast tissues [1]. Using RT-PCR we showed that the three
isoforms AKR1C1–AKR1C3 are expressed in each of the
four cell lines examined and that expression of each was
highest in MCF-10A cells. In human, all three isoforms
have been shown to be able to act as NAD(P)(H)-depend-
ent 3α-oxidoreductases, with AKR1C2 and AKR1C3 pre-
dominating in 3α-HSO activity [43,45] in prostate and
mammary glands [43]. A fourth isoform, AKR1C4 (3α-
HSO type 1), was not expressed in any of the four cell
lines, agreeing with previous findings using human breast
tissue [42].
3β-HSO activities have been noted in human breast tissue
[1] and in MCF-7 [46], T-47Dco [47] and ZR-75-1 [48]
human breast cell lines. Our data also indicates 3β-HSO
activity and mRNA expression of HSO3B1 (3β-HSO type
1) in MCF-7, MDA-MB-231, T-47D and MCF-10A breast
cell lines but no significant differences between the cell
types.
It has been suggested [49] that in hormone-related cancers
(breast, prostate, endometrium, testis, ovary, thyroid and
osteosarcoma) hormones, both endogenous and exoge-
nous, provide the stimulus along the cancer progression
pathway. Therefore anti-hormone therapies (such as
tamoxifen) are effective in stopping the progression and
thereby increase the time to recurrence and death. Unfor-
tunately hormone-related cancers invariably become
what has been called "hormone independent" and there-
upon no longer respond to the anti-hormone therapies.
Despite a large number of studies, "hormone independ-
ence" in cancer is poorly understood. Estradiol17β is con-
sidered the active hormone in most so-called hormone-
related breast cancers, and "hormone independence" im-
plies "estradiol independence". Our previous studies [1–
3] and the current report on the differences in progester-
one metabolism between tumorous and normal breast tis-
sue, tumorigenic and nontumorigenic breast cell lines and
significant actions of the progesterone metabolites on
breast cell lines, regardless of ER and PR status, lead us toBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/9
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suggest that during the breast cancer progression pathway,
change in progesterone metabolizing enzyme expression,
and hence enzyme activity profile, occur in affected breast
tissues. The resulting increases in tumor- and metastasis
promoting – and concomitant decreases in inhibitory –
progesterone metabolites may provide the stimulus for
progression and malignancy of the tumor. Aspects of the
hypothesis could be tested in vitro with breast cell lines
and in vivo with immunodefient mice, using specific stim-
ulatory and inhibitory agents for progesterone metaboliz-
ing enzyme activity and expression.
Conclusions
The findings provide the first evidence that the conversion
of progesterone to the cancer promoting 5α-pregnanes is
significantly higher in the human tumorigenic breast cell
lines, MCF-7 (ER+/PR+), MDA-MB-231 (ER-/PR-) and T-
47D (ER+/PR+), than in the nontumorigenic cell line,
MCF-10A (ER-/PR-). Although both 5αR1 and 5αR2 are
expressed by these cells, the elevated 5α-reductase activity
appears to be the result of significantly greater expression
of 5αR1. On the other hand, the activities of 3α-HSO and
20α-HSO, which result in direct conversion of progester-
one to the cancer-inhibiting 3αHP and 20αDHP, are sig-
nificantly higher in MCF-10A cells than in MCF-7, MDA-
MB-231 and T-47D cells. The higher 3α-HSO and 20α-
HSO activities correlate with significantly higher levels of
20α-HSO (AKR1C1), 3α-HSO2 (AKR1C3) and 3α-HSO3
(AKR1C2) mRNA expression in MCF-10A cells. Changes
in progesterone metabolizing enzyme expression
(resulting in enzyme activity changes) may be responsible
for promoting breast cancer progression due to increased
production of tumor-promoting 5α-pregnanes and de-
creased production of anti-cancer 20α – and 3α-4-preg-
nenes.
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